For research use only. Not for therapeutic Use.
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT)[1][2][3][4].
177Lu-DOTATATE shows excellent antitumor effects in rats[1].
Catalog Number | I045671 |
CAS Number | 177943-88-3 |
Molecular Formula | C65H90N14O19S2 |
Purity | ≥95% |
Reference | [1]. Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. [2]. Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. [3]. Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. [4]. Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. |